Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Overview
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Apollo Therapeutics LLC
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Millennium Pharmaceuticals Inc
njing Tianyi Bioscience Co Ltd
njing Transthera Biosciences Co Ltd
Taiho Pharmaceutical Co Ltd
Vichem Chemie Research Ltd
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APIOEE-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENMD-2076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3295668 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestil Tract Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Aurora A Kise for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Aurora Kise A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Dormant Products
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Discontinued Products
Aurora Kise A (Aurora 2 or Serine/Threonine Protein Kise 15 or Serine/Threonine Protein Kise 6 or Serine/Threonine Protein Kise Aurora A or Aurora/IPL1 Related Kise 1 or AURKA or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Desigtion from FDA to treat Cholangiocarcinoma
Oct 02, 2018: Finding new combition therapies for Neuroblastoma
Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
Jun 25, 2018: Combition Therapy May Revive Prospects for Embattled Breast Cancer Drugs
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076
May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma
May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC Intertiol Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by CASI Pharmaceuticals Inc, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Dormant Products, H2 2019 (Contd..6), H2 2019
Dormant Products, H2 2019 (Contd..7), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019